Wednesday, September 11, 2013
International pharmaceutical group Recordati has acquired Opalia Pharma, a Tunisian pharmaceutical company. The transaction is valued at $48 million, paid in cash, and is subject to prior approval by Tunisian authorities. Opalia Pharma markets dermatology, gastrointestinal and respiratory therapeutic products in a cGMP certified facility specialized in liquid and semi-solid forms.
Recordati, a specialty pharmaceutical group based in Italy, has successfully concluded the acquisition of all rights concerning a portfolio of products indicated for the treatment of rare and other diseases and marketed mainly in the U.S. from pharmaceutical company Lundbeck. The value of the transaction is of $100 million, of which $80 million were paid at the closing.